Pictet Asset Management (UK)’s NovoCure NVCR Stock Holding History

Pictet Asset Management (UK)’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$7.97M	Buy	35,941 +5,041	+16%	+$981K	0.01%	742
2021 Q1	$4.08M	Sell	30,900 -1,300	-4%	-$206K	﹤0.01%	874
2020 Q4	$5.57M	Buy	32,200 +25,100	+354%	+$3.43M	0.01%	792
2020 Q3	$790K	Sell	7,100 -27,023	-79%	-$2.16M	﹤0.01%	994
2020 Q2	$2.02M	Sell	34,123 -30,778	-47%	-$2.02M	﹤0.01%	863
2020 Q1	$4.37M	Buy	64,901 +12,400	+24%	+$980K	0.01%	680
2019 Q4	$4.42M	Buy	+52,501	New	+$4.24M	0.01%	789

Other funds holding NVCR

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management (UK)'s NVCR Position: Q2 2021 in Review

Pictet Asset Management (UK) increased its NovoCure (NVCR) stake by 16% in Q2 2021, buying an estimated $981K and bringing the position to 35,941 shares worth $7.97M. The position accounts for 0.01% of the portfolio, ranked #742.

Pictet Asset Management (UK) first reported a position in NVCR in Q4 2019 and has held it in 7 quarters since. 361 funds tracked by Wall St. Rank hold NVCR as of Q2 2021.

Pictet Asset Management (UK) held 35,941 shares of NovoCure worth $7.97M as of Q2 2021.
Pictet Asset Management (UK) bought 5,041 NovoCure shares in Q2 2021, an estimated $981K.
NovoCure made up 0.01% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #742 holding.
Pictet Asset Management (UK) first reported a position in NovoCure in Q4 2019 and has held it in 7 quarters since.
361 funds tracked by Wall St. Rank held NovoCure as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.